Clin2
NCT07193589Possibly a fitRecruiting

Testing ZL-82 tablets for moderate to severe eczema

Atopic Dermatitis

Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.

This study tests if an oral tablet called ZL-82 can help people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to other treatments. It aims to find a new option for controlling this chronic skin condition.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
111 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have had eczema for at least 1 year.
  • Your eczema is moderate to severe, covering at least 10% of your body.
  • You have tried prescription creams or light therapy in the past 6 months but they didn't work well enough.
  • You are willing to use a basic moisturizer twice daily for at least a week before starting the study.
  • You have not taken certain other eczema pills (like JAK inhibitors) recently.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07216027Recruiting· Phase 2
A study of a new eczema medicine for adults

This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.

Huntington Beach, California
NCT06775860Recruiting· Phase 3
Testing ICP-332 for moderate to severe eczema

This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.

Hefei, Anhui
NCT06947993Recruiting· Phase 2
Study of a new treatment for moderate to severe eczema

This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.

Birmingham, Alabama
NCT07399067Recruiting· Phase 2
Testing IBI3002 for moderate to severe eczema

This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.

Beijing, Beijing Municipality
NCT05995964Recruiting· Phase 2
Study of two new medicines for eczema

This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.

Birmingham, Alabama
NCT06487000Not yet recruiting· Phase 2
Testing EC-18 for moderate to severe eczema

This trial tests an experimental drug called EC-18 (a pill) for people with moderate to severe eczema that hasn't been controlled well with creams. It aims to see if different doses of the drug can safely reduce itching and skin rash.

Hear when a new Atopic Dermatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.